Takeda and TiGenix Announce Results of Second Acceptance Period for
the Voluntary and Conditional Public Takeover Bid in respect of TiGenix
and Commencement of Simplified Squeeze-out and Intention to Delist the
ADSs from Nasdaq...

The number of Securities tendered into the Bid, together with all
Securities owned by Takeda and its affiliates, represents or gives
access to 96.03% of the voting rights represented or given access to
by all of the outstanding Securities on a fully diluted basis.

Following settlement of the Securities, Takeda will own 96.08% of the
outstanding Ordinary Shares (including Ordinary Shares represented by
ADSs) and will have acquired 95.76% of the Ordinary Shares that were
the subject of the Bid. The conditions for a simplified squeeze-out
under Belgian law have therefore been met.

The squeeze-out period will commence today, July 6, 2018, and will
expire on July 26, 2018.

Following the squeeze-out, TiGenix will become a wholly owned
subsidiary of Takeda and the Ordinary Shares will be automatically
delisted from Euronext Brussels. TiGenix intends to effect the
delisting of the ADSs from Nasdaq, terminate the ADS Facility and
terminate TiGenix’s U.S. reporting obligations.

Takeda and TiGenix Announce Results of Second Acceptance Period for
the Voluntary and Conditional Public Takeover Bid in respect of TiGenix
and Commencement of Simplified Squeeze-out and Intention to Delist the
ADSs from Nasdaq, Terminate the ADS Facility and Terminate TiGenix’s
U.S. Reporting Obligations

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix
NV (Euronext Brussels and Nasdaq: TIG) (“TiGenix”) today announced the
results of the second acceptance period of Takeda’s previously announced
tender offer (the “Bid”) in cash for all outstanding ordinary shares
(“Ordinary Shares”), warrants (“Warrants”) and American Depositary
Shares (“ADSs,” and together with the Ordinary Shares and the Warrants,
the “Securities”) of TiGenix that are not yet owned by Takeda and its
affiliates, which expired as scheduled on July 3, 2018, at 4 p.m.
CEST/10 a.m. EDT.

The Bid, which was made pursuant to the offer and support agreement
entered into between Takeda and TiGenix on January 5, 2018 (the “Offer
and Support Agreement”), is comprised of two separate offers – (i) an
offer to all holders of Ordinary Shares and Warrants in accordance with
the applicable law in Belgium (the “Belgian Offer”) and (ii) an offer to
holders of Ordinary Shares who are resident in the U.S. in accordance
with applicable U.S. law and to holders of ADSs wherever located (the
“U.S. Offer”).

Takeda confirmed that, as of the expiration of the second acceptance
period on July 3, 2018, a total of 272,439,858 Ordinary Shares
(including 20,738,900 Ordinary Shares represented by ADSs) and a total
of 12,212,006 Warrants had been validly tendered into the Bid and not
withdrawn. As a result, taking into account all Securities owned by
Takeda and its affiliates (including Ordinary Shares issued on July 2,
2018 as a result of the exercise of Warrants by Takeda), following
settlement of the Securities tendered in the second acceptance period,
Takeda will hold 96.08% of all Ordinary Shares (including Ordinary
Shares represented by ADSs) and will have acquired 95.76% of the
Ordinary Shares that were the subject of the Bid. Payment for the
Ordinary Shares, Warrants and ADSs validly tendered and not withdrawn in
the second acceptance period is currently expected to commence on July
10, 2018.

Takeda confirms that the conditions for a simplified squeeze-out, in
accordance with articles 42 and 43 of the Belgian Royal Decree on Public
Takeover Bids and article 513 of the Belgian Companies Code, have been
met as, following settlement of the Securities tendered in the second
acceptance period, Takeda will own more than 95% of the outstanding
Ordinary Shares (including Ordinary Shares represented by ADSs) and will
have acquired more than 90% of the Ordinary Shares that were the subject
of the Bid.

The squeeze-out period for the Belgian Offer and the U.S. Offer will
commence today, July 6, 2018, at 9 a.m. CEST, and 9 a.m. EDT,
respectively, and is scheduled to expire on July 26, 2018, at 4 p.m.
CEST, and 10 a.m. EDT, respectively. The results of the squeeze-out
period are expected to be published on July 31, 2018. Payment for the
Securities validly tendered and not withdrawn in the squeeze-out period
is currently scheduled for July 31, 2018.

During the squeeze-out period, holders of Ordinary Shares, Warrants and
ADSs can tender their Securities in the Bid by following the
instructions set out in the prospectus or the tender offer statement on
Schedule TO, as applicable to them.

Ordinary Shares (including Ordinary Shares represented by ADSs) and
Warrants not tendered into the squeeze-out will be deemed transferred to
Takeda by operation of Belgian law at the end of the squeeze-out period.
The funds necessary to pay for untendered Ordinary Shares (including
Ordinary Shares represented by ADSs) and Warrants will be deposited with
the Belgian Bank for Official Deposits (Deposito- en Consignatiekas /
Caisse des Dépôts et Consignations) in favor of the holders of
Ordinary Shares and Warrants who did not previously tender into the
squeeze-out.

Following the squeeze-out, TiGenix will become a wholly owned subsidiary
of Takeda and the Ordinary Shares will be automatically delisted from
Euronext Brussels. As further described below, TiGenix also intends to
delist the ADSs from the Nasdaq Global Select Market (“Nasdaq”),
terminate the ADS Facility and terminate its U.S. reporting obligations.

“Takeda and TiGenix are pleased to announce the successful progression
of this transaction as we move forward with the integration of the two
companies,” said Asit Parikh, Head of Takeda’s Gastroenterology
Therapeutic Area Unit. “We are excited about our future together, as
well as the benefit we can provide to patients with GI disorders. As we
look ahead, we are aiming to be fully integrated by the end of our
fiscal year to ensure we can continue to build on the value we’re
providing to those with GI disorders as quickly and efficiently as
possible.”

TiGenix’s intention to delist the ADSs from Nasdaq, terminate the ADS
Facility and terminate its U.S. reporting obligations.

TiGenix is notifying The Nasdaq Stock Market today of its determination
to withdraw the ADSs from listing on Nasdaq and to withdraw the
registration of the Ordinary Shares under Section 12(b) of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”).
TiGenix’s board of directors (the “Board of Directors”) intends to cause
TiGenix to file a Form 25 with the U.S. Securities and Exchange
Commission (the “SEC”) on or about July 16, 2018, to effect the
delisting and withdrawal from registration under Section 12(b) of the
Exchange Act. TiGenix expects the Form 25 to become effective 10 days
after it is filed, unless TiGenix withdraws it or the SEC postpones its
effectiveness, at which point the ADSs will no longer trade on Nasdaq.
Once the Form 25 becomes effective, the Board of Directors intends to
cause TiGenix to request the termination of the existing deposit
agreement among TiGenix, Deutsche Bank Trust Company Americas and
holders of the ADSs (the “ADS Facility”). The Board of Directors also
intends to cause TiGenix to file a Form 15F with the SEC to deregister
with the SEC and terminate TiGenix’s U.S. reporting obligations once the
Board of Directors confirms that the applicable conditions to do so are
met.

Subject to compliance with applicable regulations, the Board of
Directors has determined to withdraw the ADSs from listing on Nasdaq, to
terminate the ADS Facility and to withdraw the registration of the
Ordinary Shares under the Exchange Act based on the fact that following
consummation of the squeeze-out, TiGenix will be wholly owned by Takeda.

TiGenix has not arranged for the listing of ADSs on any other national
securities exchange and has not made any arrangements for the quotation
of ADSs in a quotation medium (as defined under applicable SEC rules and
regulations).

TiGenix reserves the right, for any reason, to delay the filings
mentioned herein, to withdraw them prior to effectiveness, and to
otherwise change its plans in respect of delisting, termination of the
ADS Facility, deregistration and termination of its U.S. reporting
obligations.

Takeda’s Commitment to Gastroenterology

Gastrointestinal (GI) diseases can be complex, debilitating and
life-changing. Recognizing this unmet need, Takeda and our collaboration
partners have focused on improving the lives of patients through the
delivery of innovative medicines and dedicated patient disease support
programs for over 25 years. Takeda aspires to advance how patients
manage their disease. Additionally, Takeda is leading in areas of
gastroenterology associated with high unmet need, such as inflammatory
bowel disease, acid-related diseases and motility disorders. Our GI
research & development team is also exploring solutions in celiac
disease, advanced liver disease and microbiome therapies.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research
and development-driven pharmaceutical company committed to bringing
better health and a brighter future to patients by translating science
into life-changing medicines. Takeda focuses its R&D efforts on
oncology, gastroenterology and neuroscience therapeutic areas plus
vaccines. Takeda conducts R&D both internally and with partners to stay
at the leading edge of innovation. Innovative products, especially in
oncology and gastroenterology, as well as Takeda’s presence in emerging
markets, are currently fueling the growth of Takeda. Approximately
30,000 Takeda employees are committed to improving quality of life for
patients, working with Takeda’s partners in health care in more than 70
countries. For more information, visit https://www.takeda.com/newsroom/.

About TiGenix

TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced
biopharmaceutical company developing novel therapies for serious medical
conditions by exploiting the anti-inflammatory properties of allogeneic,
or donor-derived, stem cells. TiGenix is headquartered in Leuven
(Belgium) and has operations in Madrid (Spain) and Cambridge, MA (USA).
For more information, please visit http://www.tigenix.com.

Forward-looking information

This press release may contain forward-looking statements and estimates
with respect to the anticipated future performance of TiGenix and the
market in which it operates, statements regarding the expected
consummation of the tender offer and statements regarding the expected
timeline for TiGenix’s filing of the Form 25, the delisting of the ADSs
from the Nasdaq Global Select Market and TiGenix’s deregistration and
termination of U.S. reporting obligations, which involves a number of
risks and uncertainties, including the possibility that the transaction
will not be completed, the impact of general economic, industry, market
or political conditions, and the other risks and uncertainties discussed
in TiGenix’s public filings with the SEC, including the “Risk Factors”
section of TiGenix’s Form 20-F filed on April 16, 2018, as well as the
tender offer documents filed by Takeda on April 30, 2018, as amended or
supplemented from time to time, and the solicitation/recommendation
statement filed by TiGenix on April 30, 2018, as amended or supplemented
from time to time. Certain of these statements, forecasts and estimates
can be recognized by the use of words such as, without limitation,
“believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”,
“estimates”, “may”, “will” and “continue” and similar expressions. They
include all matters that are not historical facts. Such statements,
forecasts and estimates are based on various assumptions and assessments
of known and unknown risks, uncertainties and other factors, which were
deemed reasonable when made but may or may not prove to be correct.
Actual events are difficult to predict and may depend upon factors that
are beyond TiGenix’s control. Therefore, actual results, the financial
condition, performance, timing or achievements of TiGenix, or industry
results, may turn out to be materially different from any future
results, performance or achievements expressed or implied by such
statements, forecasts and estimates. Given these uncertainties, no
representations are made as to the accuracy or fairness of such
forward-looking statements, forecasts and estimates. Furthermore,
forward-looking statements, forecasts and estimates only speak as of the
date of the publication of this press release. Takeda and TiGenix
disclaim any obligation to update any such forward-looking statement,
forecast or estimates to reflect any change in TiGenix’s expectations
with regard thereto, or any change in events, conditions or
circumstances on which any such statement, forecast or estimate is
based, except to the extent required by Belgian law.

This communication constitutes communication within the scope of article
31 and 33 of the Belgian Law of April 1, 2007 on public takeover bids.

The tender offer for the Ordinary Shares, Warrants and ADSs has
commenced. This communication is for informational purposes only and is
neither a recommendation, an offer to purchase nor a solicitation of an
offer to sell any securities of TiGenix.

Security holders of TiGenix are urged to read the offer documents which
are available at www.sec.gov.
The U.S. Offer is being made pursuant to an offer to purchase and
related materials. Takeda has filed a tender offer statement on Schedule
TO with the SEC with respect to the U.S. Offer on April 30, 2018, as
amended or supplemented from time to time. TiGenix has filed a
solicitation/recommendation statement on Schedule 14D-9 with the SEC
with respect to the U.S. Offer on April 30, 2018, as amended or
supplemented from time to time.

Holders of ADSs and Ordinary Shares subject to the U.S. Offer who wish
to participate in the U.S. Offer, are urged to carefully review the
documents relating to the U.S. Offer that has been filed by Takeda with
the SEC, as amended or supplemented from time to time, since these
documents contain important information, including the terms and
conditions of the U.S. Offer. Holders of ADSs and Ordinary Shares
subject to the U.S. Offer who wish to participate in the U.S. Offer, are
also urged to read the related solicitation/recommendation statement on
Schedule 14D-9 relating to the U.S. Offer that has been filed with the
SEC by TiGenix, as amended or supplemented from time to time, since it
contains important information. You may obtain a free copy of these
documents and other documents at the SEC’s website at www.sec.gov.
Investors and security holders may also obtain free copies of the
solicitation/recommendation statement on Schedule 14D-9, as amended or
supplemented from time to time, and other documents filed with the SEC
by TiGenix at www.tigenix.com.
The Schedule TO, including the offer to purchase and related materials,
and the Schedule 14D-9, including the solicitation/recommendation
statement, may also be obtained for free by contacting Georgeson LLC,
the information agent for the tender offer, at +1 866 391 6921/tig-offer@georgeson.com.
In addition to the offer and certain other tender offer documents, as
well as the solicitation/recommendation statement, TiGenix files reports
and other information with the SEC. You may read and copy any reports or
other information filed by TiGenix at the SEC Public Reference Room at
100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at
1-800-SEC-0330 for further information on the Public Reference Room.
TiGenix’s filings at the SEC are also available to the public from
commercial document-retrieval services and at the website maintained by
the SEC at www.sec.gov.

YOU SHOULD READ THE FILINGS MADE BY TAKEDA AND TIGENIX WITH THE SEC
CAREFULLY BEFORE MAKING A DECISION CONCERNING THE U.S. OFFER.